Your fact-checks will appear here
The FDA warning about LipoFit Turbo due to the presence of undisclosed prescription drugs and diuretics
Since the ’s November 27, 2024 advisory warning consumers not to buy or use , publicly available agency materials show the product was laboratory-tested and found to contain undeclared prescription dr...
Turbo — a weight‑loss product marketed as a dietary supplement — has been the subject of direct FDA laboratory analysis, which found concealed prescription drugs in the product . Separately, “LipoFit”...
The available notice names as a product consumers should avoid, based on laboratory analysis that found undisclosed prescription drugs and diuretics in the formulation , but the documents provided in ...